Acumen Pharmaceuticals Q1 2026 Earnings Report

Acumen Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.40
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Acumen Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Acumen Pharmaceuticals Announcement Details

• Quarter: Q1 2026
• Date: 5/12/2026
• Time: Before Market Opens
• Conference Call Date: Tuesday, May 12, 2026
• Conference Call Time: 8:00AM ET

Acumen Pharmaceuticals (NASDAQ:ABOS) is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development. Its most advanced program targets abnormal tau aggregation in Alzheimer’s disease and has entered Phase 1 clinical testing. Additional preclinical candidates are designed to inhibit the misfolding or aggregation of proteins including TDP-43, alpha-synuclein, mutant huntingtin and transthyretin, with the goal of expanding its portfolio across a spectrum of neurodegenerative indications.

Founded in 2019 and headquartered in San Diego, California, Acumen Pharmaceuticals has assembled a management team with extensive experience in small molecule drug discovery and neuroscience R&D. The company completed its initial public offering in mid-2023, raising capital to advance its lead program through clinical proof-of-concept and to prepare select preclinical candidates for first-in-human studies. Acumen’s research and development efforts are complemented by collaborations with academic laboratories and contract research organizations across North America.

With a strategic focus on oral therapies that can be broadly administered in outpatient settings, Acumen aims to address significant unmet medical needs in the rapidly growing field of neurodegenerative disease treatment. The company’s leadership emphasizes rigorous translational science and biomarker-driven clinical development to accelerate the pathway from discovery to potential regulatory approval, ultimately seeking to improve quality of life for patients worldwide.